SEED Advances Cancer Drug Into Human Trials, Targets Hard-to-Treat Tumors
KING OF PRUSSIA, PA — SEED Therapeutics has advanced its lead cancer drug candidate, ST-01156, into a first-in-human clinical trial, a step that will test whether the company’s molecular glue …
SEED Advances Cancer Drug Into Human Trials, Targets Hard-to-Treat Tumors Read More